Mechanical Circulatory Support in Infarct-Related Cardiogenic Shock, Anticoagulation Benefit in Device-Detected AFib, Semaglutide in HFpEF Patients

In this week's View, Dr. Eagle looks at temporary mechanical circulatory support in infarct-related cardiogenic shock. He then explores the anticoagulation benefit in device-detected atrial fibrillation with or without vascular disease as reported in a combined analysis of the NOAH-AFNET 6 and ARTESiA trials. Finally, Dr. Eagle discusses a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomized trials that documented the effectiveness of semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction.

Subscribe to Eagle's Eye View